Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?
Satoshi MatsuiAtsushi KudoToshiro OguraKosuke OgawaHiroaki OnoYusuke MitsunoriDaisuke BanShinji TanakaMinoru TanabePublished in: Journal of cancer research and clinical oncology (2019)
Dose reduction of sunitinib did not alter tumor shrinkage rates or prognoses for patients with advanced Pan-NENs.